VFA
CYTK icon

Virtus Fund Advisers’s Cytokinetics CYTK Stock Holding History

Virtus Fund Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-789
Closed -$65.9K – 120
2023
Q4 		$65.9K Hold
789
– – 0.41% 35
2023
Q3 		$23.2K Buy
789
+239
+43% +$7.96K 0.16% 91
2023
Q2 		$17.9K Hold
550
– – 0.13% 97
2023
Q1 		$19.4K Sell
550
-373
-40% -$15.2K 0.14% 101
2022
Q4 		$42.3K Buy
+923
New +$39.7K 0.3% 64
2017
Q4 		$348K Buy
+42,645
New +$484K ﹤0.01% 408
2014
Q3 		– Sell
-2,952
Closed -$14K – 1343
2014
Q2 		$14K Buy
+2,952
New +$18K ﹤0.01% 2626

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Virtus Fund Advisers's CYTK Position: Q1 2024 in Review

Virtus Fund Advisers sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 789 shares — an estimated $65.9K sold.

Virtus Fund Advisers first reported a position in CYTK in Q2 2014 and held it in 7 quarters. The position peaked at $348K in Q4 2017. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Virtus Fund Advisers reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Virtus Fund Advisers sold 789 Cytokinetics shares in Q1 2024, an estimated $65.9K.
  • Virtus Fund Advisers first reported a position in Cytokinetics in Q2 2014 and held it in 7 quarters.
  • Virtus Fund Advisers's Cytokinetics position peaked at $348K in Q4 2017.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Virtus Fund Advisers's 13F filing for Q1 2024, filed 15 May 2024.